AI Status in Clinical Development

*This report is available to download at no cost for registered users only. Once your account is created, you may add the report to your cart (any license level) and complete a zero-dollar order to access the downloadable PDF.

AI talk is everywhere. For this report, though, we’re not talking about how your kids use ChatGPT to do their homework. If you watch any financial television show, it’s full of discussions about how AI will/could change our lives. Depending on the way the wind blows, AI could be seen as the destroyer of industries (SaaS) or the creator of some of the most valuable companies in the world (Nvidia).

Clinical development encompasses so many diverse technologies, processes, and regulatory frameworks that we did not want to narrow the scope of this research. Respondents in this survey come from a wide variety of roles and responsibilities, and we think this provides a great, high-level industry perspective. There are many specific applications of AI mentioned by respondents. Please read the verbatim responses in the Appendix section to get the full picture of their perspectives and how they are using AI.

Make no mistake, there is no stopping AI:

• Only four potential respondents were screened out from this research because they didn’t use AI at work
• Respondents report using ~3 commercial / off-the-shelf AI applications at work in the past six months
• However, nearly half of respondents indicated their company did NOT have SOPs or guidelines as to how AI is to be used
• Trust in AI outputs is only moderate
• Use cases range from complex (predicting a protein’s 3D structure) to the administrative (taking meeting notes or summarizing documents)

We didn’t set out to solve any particular problem with this report, but simply to shed light on the current state of AI in clinical development and, perhaps, track use cases over time.

Please enjoy, and we encourage you to share this complimentary resource with anyone in our industry.

Respondent profile (n=125):

• All respondents work at a sponsor pharmaceutical or biotechnology company
• Two-thirds of the respondents are from the US, the other third is from Europe
• All respondents are at least “slightly knowledgeable” about AI in clinical development/trials
• 90% of respondents hold a title of “Director” or higher